Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M92.4Revenue (TTM) $M23.0Net Margin (%)-93.6Altman Z-Score-5.2
Enterprise Value $M81.1EPS (TTM) $-1.0Operating Margin %-73.4Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.5Pre-tax Margin (%)-94.3Higher ROA y-yY
Price/Book2.410-y EBITDA Growth Rate %--Quick Ratio4.2Cash flow > EarningsY
Price/Sales2.75-y EBITDA Growth Rate %--Current Ratio4.6Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-38.6Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-90.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M31.9ROIC % (ttm)-94.4Gross Margin Increase y-yN

Gurus Latest Trades with CRME

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CRMEJulian Robertson 2012-12-31 Sold Out -0.11%$1.25 - $2.5
($1.57)
$ 2.9085%Sold Out0
CRMEJulian Robertson 2011-12-31 Reduce-0.48%$9.35 - $17.85
($13.14)
$ 2.90-78%Reduce -18.26%319,221
CRMEGeorge Soros 2011-12-31 Sold Out -0.0008%$9.35 - $17.85
($13.14)
$ 2.90-78%Sold Out0
CRMEJulian Robertson 2011-09-30 Reduce-0.69%$16.45 - $27.95
($19.93)
$ 2.90-85%Reduce -22.89%390,518
CRMEGeorge Soros 2011-09-30 Add$16.45 - $27.95
($19.93)
$ 2.90-85%Add 4.55%2,760
CRMEGeorge Soros 2011-06-30 Buy $19.25 - $28.85
($23.59)
$ 2.90-88%New holding2,640
CRMEJulian Robertson 2011-03-31 Add0.16%$21.3 - $34.95
($29.29)
$ 2.90-90%Add 6.15%506,468
CRMEJulian Robertson 2010-12-31 Add0.34%$23 - $32.75
($27.99)
$ 2.90-90%Add 9.55%477,123
CRMEGeorge Soros 2010-12-31 Sold Out $23 - $32.75
($27.99)
$ 2.90-90%Sold Out0
CRMEJulian Robertson 2010-09-30 Add0.4%$29.85 - $46.55
($36.3)
$ 2.90-92%Add 10.01%435,523
CRMEGeorge Soros 2010-09-30 Reduce$29.85 - $46.55
($36.3)
$ 2.90-92%Reduce -3.67%2,100
CRMEJulian Robertson 2010-06-30 Buy 3.53%$33.05 - $43.4
($40.09)
$ 2.90-93%New holding395,881
CRMEGeorge Soros 2010-06-30 Buy $33.05 - $43.4
($40.09)
$ 2.90-93%New holding2,180
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CRME is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


CRME: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Archibald, JenniferSenior Officer 2014-09-08Buy75$7.29-60.22view
Archibald, JenniferSenior Officer 2014-09-05Buy4,100$7.25-60view
Archibald, JenniferSenior Officer 2014-09-05Buy100$7.22-59.83view
Archibald, JenniferSenior Officer 2014-09-05Buy3,259$6.7-56.72view
Hunter, William L.Director, Senior Officer 2014-09-05Buy31,000$6.74-56.97view
Hunter, William L.Director, Senior Officer 2014-09-04Buy19,000$6.65-56.39view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-27Sell2,000$8.65-66.47view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-26Sell1,500$8.65-66.47view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-25Sell300$8.63-66.4view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-25Sell2,000$8.64-66.44view

Press Releases about CRME :

Quarterly/Annual Reports about CRME:

    News about CRME:

    Articles On GuruFocus.com
    A Closer Look Into Veritas Pharma Apr 21 2016 
    Julian Robertson’s "smart idea, grounded on exhaustive research, followed by a big bet" Jun 24 2011 
    Julian Robertson’s Tiger Management Q1 Portfolio Update May 16 2011 
    Julian Robertson Keeps Buying CRME, Selling AAPL Apr 13 2011 
    More Word of Wisdom from Julian Robertson; Top 2Q10 Purchases: GOOG, EBAY, AAPL, CRME, GS Nov 04 2010 

    More From Other Websites
    11:56 am Cardiome Pharma launches XYDALBA in the UK earlier than expected Dec 08 2016
    Cardiome Announces Commercial Launch of Xydalba™ (dalbavancin) in the UK Dec 08 2016
    Cardiome Announces Commercial Launch of Xydalba™ (dalbavancin) in the UK Dec 08 2016
    Cardiome Advances Toward the UK XYDALBA™ (dalbavancin) Launch Nov 29 2016
    Cardiome Advances Toward the UK XYDALBA™ (dalbavancin) Launch Nov 29 2016
    Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016 Nov 09 2016
    Cardiome reports 3Q loss Nov 07 2016
    Cardiome reports 3Q loss Nov 07 2016
    Cardiome Reports Third Quarter 2016 Financial Results Nov 07 2016
    Cardiome Reports Third Quarter 2016 Financial Results Nov 07 2016
    Cardiome to Reschedule Release of Third Quarter 2016 Financial Results Nov 01 2016
    Cardiome to Reschedule Release of Third Quarter 2016 Financial Results Nov 01 2016
    Cardiome to Hold Third Quarter 2016 Financial Results Conference Call on November 7 Oct 28 2016
    Cardiome to Hold Third Quarter 2016 Financial Results Conference Call on November 7 Oct 28 2016
    New Strong Sell Stocks for October 26th Oct 26 2016
    New Strong Sell Stocks for October 14th Oct 14 2016
    Cardiome Announces Initiation of Commercial Operations in Canada, Eh Oct 14 2016
    Cardiome Announces Initiation of Commercial Operations in Canada, Eh Oct 14 2016
    Cardiome Announces Recent Insider Purchases Aug 16 2016
    Cardiome Announces Recent Insider Purchases Aug 16 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)